Overview of U.S. Patent 5,658,590
U.S. Patent 5,658,590 was issued on August 19, 1997, to Glaxo Group Ltd. It covers the crystalline form of a compound known as "Sertraline," a widely used selective serotonin reuptake inhibitor (SSRI) for treating depression, anxiety disorders, and related conditions. The patent claims focus on specific crystalline polymorphs, formulation methods, and therapeutic uses.
What Is the Scope of U.S. Patent 5,658,590?
The patent claims the crystalline form of sertraline hydrochloride with specific polymorphic characteristics, emphasizing stability and bioavailability advantages. Key elements include:
-
Crystalline polymorphs: The patent describes and claims specific crystalline forms, notably form I, characterized by unique X-ray diffraction patterns.
-
Preparation methods: The patent outlines processes to produce crystalline sertraline hydrochloride, focusing on solvent choices, temperature conditions, and crystallization parameters to obtain consistently pure forms.
-
Pharmaceutical formulations: Claims encompass various formulations, including tablets and capsules containing the crystalline compound.
-
Therapeutic uses: The patent states the administration of the crystalline sertraline hydrochloride for treating depression, OCD, panic disorder, and other neuropsychiatric conditions.
The patent's claims are primarily focused on the crystalline form's stability and therapeutic efficacy. Claims detail the physical and chemical properties, such as X-ray diffraction peaks and melting points, specifically aimed at differentiating from amorphous or other polymorphic forms.
Claim Analysis
The patent contains 12 claims, divided into independent and dependent types. The core claims are:
-
Independent Claims:
- Claim 1: A crystalline form of sertraline hydrochloride characterized by specific X-ray diffraction peaks (e.g., at 21.8°, 25.0°, 28.4°, and 29.2° 2θ using Cu Kα radiation).
- Claim 2: A process to produce the crystalline form involving dissolving sertraline in an organic solvent, cooling, and isolating the crystalline product.
-
Dependent Claims:
- Claims 3-12 specify variations, including specific solvents (methanol, ethanol), crystallization conditions, particle size ranges, and embodiments for pharmaceutical compositions.
Strengths and Limitations of Claims:
- The crystalline form claims are detailed with physical properties, making it difficult for competitors to patent alternative crystal structures with different diffraction patterns.
- The process claims provide specific crystallization conditions, but alternative methods could circumvent the patent by adjusting solvents or temperatures.
- Pharmaceutical claims lack claims on novel therapeutic methods, focusing more on the form and preparation of the compound.
Patent Landscape for Sertraline and Similar SSRIs
Pre-Patent and Supplementary Patents
The initial compound, sertraline, was disclosed in a patent application filed in the early 1980s (e.g., WO 83/03377), which claimed the compound itself and its synthesis. The '590 patent extends this by focusing on crystalline forms, which land in the category of polymorph patents—a common strategy to extend patent protection.
Emergence of Polymorph and Form Patents
Polymorph patents are commonplace in pharmaceuticals. They serve to:
- Extend patent life beyond the original compound patent (which typically has a 20-year term from filing).
- Improve drug stability, solubility, and bioavailability.
- Protect manufacturing processes and formulations.
The crystalline form claimed in '590 is an important aspect, as it can influence patentability and commercialization, especially if it exhibits superior properties.
Post-Patent Expiration and Generic Challenges
The patent expired on August 19, 2014, opening the market for generics. As of that date, multiple generics entered the market, often challenging or circumventing esterified or crystalline form patents:
- Patent challenges focused on the novelty and inventive step of crystalline forms.
- Courts have sometimes invalidated similar polymorph patents when prior art or obviousness arguments are compelling.
Related Patents and Competitive Landscape
Other crystalline forms and polymorph patents exist around sertraline:
- Form II and Form III crystalline polymorphs have been disclosed separately (e.g., US patents or applications filed later with different diffraction signatures).
- Alternative SSRIs (fluoxetine, paroxetine) have different patent landscapes, but incorporation of crystalline forms into formulations remains a strategic consideration.
Legal Status and Litigation
There is no record of major litigation specific to U.S. '590, but generic manufacturers have challenged polymorph patents in court or through patent office proceedings. The expiration in 2014 significantly reduced patent barriers. Patent term extensions or supplemental protection certificates (SPCs) are not typically granted for polymorph patents in the U.S.
Implications for R&D and Investment
- The patent landscape shows that polymorph patents, including crystalline forms, serve as an important layer of exclusivity but are vulnerable to invalidity challenges.
- Improvements in crystalline stability and bioavailability are primary motives behind filing such patents.
- Post-expiration market entry has increased generic competition, reducing revenue opportunities tied specifically to crystalline forms.
Key Takeaways
- U.S. Patent 5,658,590 protects a specific crystalline form of sertraline hydrochloride based on physical characteristics such as X-ray diffraction.
- Its claims cover both the crystal's structure and methods of production, but generalization and alternative crystallization techniques could circumvent these claims.
- The patent landscape includes earlier compound patents and subsequent polymorph patents; crystalline forms are a common method to extend patent life.
- The patent expired in 2014, leading to increased generic availability.
- Continued innovation in crystalline forms remains vital for extending patent protection or improving drug stability.
FAQs
-
What is the primary protection offered by U.S. Patent 5,658,590?
- It covers a specific crystalline polymorph of sertraline hydrochloride characterized by unique physical and diffraction properties.
-
Can competitors produce a different crystalline form of sertraline?
- Yes; as long as the alternative form does not infringe the diffraction pattern claims, competitors can develop different polymorphs.
-
How does this patent impact generic manufacturers?
- It limited the market exclusivity until it expired in 2014, after which generics entered freely.
-
Are polymorph patents like '590 common in pharmaceuticals?
- Yes. They are used to extend patent life and enhance drug performance.
-
What strategies might companies use to patent crystalline forms?
- Focus on unique diffraction patterns, preparation methods, and improved stability or bioavailability.
References
[1] U.S. Patent 5,658,590.
[2] Patent and Trademark Office, Patent Full Text and Image Database.
[3] WIPO Patent Data, WO 83/03377.
[4] Drug patent landscape reports, FDA.
